Journal
ARCHIVES OF VIROLOGY
Volume 157, Issue 4, Pages 733-738Publisher
SPRINGER WIEN
DOI: 10.1007/s00705-011-1210-x
Keywords
Pseudomonas aeruginosa; Bacteriophage; Therapeutic phage; Genomes
Categories
Funding
- Kochi System Glycobiology Center, Kochi, Japan [22890129]
- Center of Biomembrane Functions Controlling Biological Systems, Kochi, Japan
- Grants-in-Aid for Scientific Research [23591391, 22890129, 24791025] Funding Source: KAKEN
Ask authors/readers for more resources
Bacteriophage (phage) KPP10 has been used in experimental phage therapies directed against P. aeruginosa infections. To examine the eligibility of phage KPP10 as a therapeutic phage, its genome was analyzed. The genomic DNA was shown to be 88,322 bp long, with 158 open reading frames (ORFs), and three tRNA genes were predicted. No ORF-encoded pathogenicity or lysogenization factor was predicted. A comparative genomic analysis revealed that phage KPP10, together with phage PAK_P3, can be grouped as a new type of lytic phage infecting P. aeruginosa. Phage KPP10 is considered to be suitable for therapeutic purposes because it is a lytic phage without ORF-encoded pathogenicity or a lysogenization factors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
